share_log

国投证券4月19日发布研报称，给予兴齐眼药（300573.SZ）买入评级，目标价格为241.50元。评级理由主要包括：1）核心产品持续放量，助力公司业绩稳定增长；2）重点品种环孢素滴眼液纳入医保后销售持续高增长。（每日经济新闻）

SDIC Securities released a research report on April 19 stating that it gave Sinqi Pharmaceutical (300573.SZ) a purchase rating, and the target price was 241.50 yuan. The main reasons for the rating include: 1) continued release of core products to help th

Zhitong Finance ·  Apr 19 09:25
SDIC Securities released a research report on April 19 stating that it gave Sinqi Pharmaceutical (300573.SZ) a purchase rating, and the target price was 241.50 yuan. The main reasons for the rating include: 1) continued release of core products to help the company's performance grow steadily; 2) sales of key varieties of ciclosporin eye drops continued to grow at a high rate after being included in medical insurance. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment